Answers are grounded in this paper and cite their sources.
Stress plays a role in tumourigenesis through catecholamines acting at β‐adrenoceptors including β 1 ‐, β 2 ‐ and β 3 ‐adrenoceptors, and the use of β‐adrenoceptor antagonists seems to counteract tumour growth and progression. Preclinical evidence and meta‐analysis data demonstrate that melanoma shows a positive response to β‐adrenoceptor blockers and in particular to propranolol acting mainly at β 1 ‐ and β 2 ‐adrenoceptors. Although evidence suggesting that β 3 ‐adrenoceptors may play a role as a therapeutic target in infantile haemangiomas has been recently reviewed, a comprehensive analysis of the data available from preclinical studies supporting a possible role of β 3 ‐adrenoceptors in melanoma was not available. Here, we review data from the literature demonstrating that propranolol may be effective at counteracting melanoma growth, and we provide preclinical evidence that β 3 ‐adrenoceptors may also play a role in the pathophysiology of melanoma, thus opening the door for further clinical assays trying to explore β 3 ‐adrenoceptor blockers as novel alternatives for its treatment. Linked Articles This article is part of a themed section on Adrenoceptors—New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc
No takes yet. Share an insight, caveat, or question.
Monte et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: